Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06234488 · ClinicalTrials.gov registry record
Multi-Institutional Transgender & Gender-Diverse Breast Cancer Study
A clinical trial of Breast Cancer and Breast Neoplasms, sponsored by Medical College of Wisconsin.
- Active
- Registry status
- 125
- Enrollment target
- 20
- Study locations
NCT06234488: Active study of Breast Cancer and Breast Neoplasms, sponsored by Medical College of Wisconsin.
NCT06234488 is a study of Breast Cancer and Breast Neoplasms that is active but no longer recruiting, run by Medical College of Wisconsin. The registered enrollment target is 125 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (96% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06234488, a study of Breast Cancer and Breast Neoplasms, is active but no longer recruiting, sponsored by Medical College of Wisconsin.
- ACTIVE NOT RECRUITING
- Registry status
- 125 participants
- Enrollment target
- 20
- Study locations
Study Summary
There is no granular retrospective data on breast cancer in transgender and gender-diverse (TGD) persons from a contemporary and diverse American cohort. The purpose of this investigation is to aggregate data from multiple institutions to describe the risk, diagnosis, management, and outcomes of TGD persons with breast cancer in effort to identify opportunities for future intervention studies to eliminate breast cancer disparities for this population.
Primary Outcome
Describe the method of breast cancer diagnosis (self detected vs screen detected vs healthcare provider detected) and compare to the published data from cisgender women by determining means and standard deviation and comparing rates using the Wilcoxon signed-rank test.
Conditions Studied
Study Locations (20)
Illinois
- Northwestern Medicine - Chicago
- Rush University Medical Center - Chicago
- NorthShore University Health System - Evanston
Massachusetts
- Massachusetts General Hospital - Boston
- Birgham and Women's Hospital - Boston
- Boston University (Boston U) - Boston
California
- University of Southern California/Los Angeles (USC/LA County) - Los Angeles
- University of California San Francisco (UCSF) - San Francisco
Florida
- Mayo Clinic - Jacksonville
- Moffitt Cancer Center (MCC) - Tampa
New York
- New York University (NYU) - New York
- University of Rochester - Rochester
Colorado
- University of Colorado Anschutz Medical Campus (CU Anschutz) - Aurora
District of Columbia
- MedStar Georgetown University Hospital (MGUH) - Washington D.C.
Michigan
- University of Michigan - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2023-12-08 |
| Est. Completion | 2026-08-30 |
What the registry record for NCT06234488 still lists
NCT06234488 is an observational study that tracks outcomes without assigning an intervention. The registered 125 participants enrollment target is mid-sized for trials with a published cap, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (96% lower).
The record links to 7 conditions, with Breast Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT06234488 names 20 study sites across 13 states, led by Illinois, Massachusetts, California.
Frequently Asked Questions
What is clinical trial NCT06234488 about?
NCT06234488 is a clinical study titled "Multi-Institutional Transgender & Gender-Diverse Breast Cancer Study". There is no granular retrospective data on breast cancer in transgender and gender-diverse (TGD) persons from a contemporary and diverse American cohort. The purpose of this investigation is to aggregate data from multiple institutions to describe the risk, diagnosis, management, and outcomes of TGD...
What is the current status of trial NCT06234488?
This trial is currently active not recruiting. The enrollment target is 125 participants. The study started on 2023-12-08. Estimated completion is 2026-08-30.
What conditions does trial NCT06234488 study?
This clinical trial studies the following conditions: Breast Cancer, Breast Neoplasms, Breast Adenocarcinoma, Breast Cancer Stage IV, Breast Cancer Invasive.
Who is sponsoring clinical trial NCT06234488?
This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06234488 being conducted?
This trial has 20 study locations across California, Colorado, District of Columbia, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06234488's enrollment target sits among peer trials
125 499th of 1224 higher than 722 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Surviving Daily Life
RECRUITING
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
UNC Pleural Fluid Registry
RECRUITING
-
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
RECRUITING · NA
-
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02717039 · 125 participants
Pharmacogenomics of Heparin-Induced Thrombocytopenia
- NCT02763033 · 125 participants · Phase 2
Dietary Manipulation of the Microbiome-metabolomic Axis for Mitigating GVHD in Allo HCT Patients
- NCT02793999 · 125 participants
Perinatal Brain Injury: Potential of Innovative NIRS to Optimize Hypothermia
- NCT03003299 · 125 participants · NA
PARTNER 3 Trial - Aortic Valve-in-Valve
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI